Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Tuesday, November 21, 2017
 
Recommended for you
Texas Instruments: The Next Dividend Aristocrat
Seeking Alpha • Paul Anderson
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
MarketWatch • Emmacourt, Reporter
Is the NHS being taken for a ride on drug prices? We need to know | Nils Pratley
The Guardian • Nils Pratley
Roche sues Pfizer to prevent a biosimilar from entering US market
Becker's Hospital Review • Alia Paavola
Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth
Seeking Alpha • William Stamm
New Div On The Block Quarterly Earnings Round-Up II: Part 2
Seeking Alpha
Understanding Aducanumab's Potential In Alzheimer's
Seeking Alpha • Slingshot Insights
Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise
Reuters • Reuters Staff
Drug firm Concordia overcharged NHS with 6,000% price rise
The Guardian • Julia Kollewe
Pfizer Inc. 2017 Q3 - Results - Earnings Call Slides
Seeking Alpha
 
Recommended for You
Finance, Investment Industry
Texas Instruments: The Next Dividend Aristocrat
Seeking AlphaPaul Anderson
Summary Texas Instruments has raised its dividend by an average of 28% over the past 2 years. TXN has increased its dividend for 14 consecutive years. Wall Street has really taken to liking TXN’s dedication to shareholders. Dividend Growth Investors (DGIs) focus...
Share
Finance, GlaxoSmithKline plc
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
MarketWatchEmmacourt, Reporter
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just...
Share
GlaxoSmithKline plc, Hedge Funds
Is the NHS being taken for a ride on drug prices? We need to know | Nils Pratley
The GuardianNils Pratley
The Competition and Markets Authority (CMA) has discovered a rich seam for inquiries – pharmaceutical companies allegedly gouging the National Health Service. Pfizer, together with a small UK company called Flynn Pharma, was fined £90m last December for “excessive and unfair” pricing...
Share
Cancer, Pfizer, Inc.
Roche sues Pfizer to prevent a biosimilar from entering US market
Becker's Hospital ReviewAlia Paavola
Roche Holding AG sued Pfizer in a move to prevent a biosimilar version of its breast cancer drug Herceptin from entering the U.S. market, according to Bloomberg. The lawsuit, filed Friday in a Delaware federal court, claims that Pfizer will violate 40...
Share
Economic Policy, Finance
Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth
Seeking AlphaWilliam Stamm
Summary Johnson & Johnson total return over-performed the DOW average for my 58.0 month test period by 33.72%, which is great. Johnson & Johnson Has increased its dividend for 55 years in a row (a dividend king) and presently has a yield...
Share
Abbott Laboratories, Accounting
New Div On The Block Quarterly Earnings Round-Up II: Part 2
Seeking Alpha
Summary As we pass the middle of the final quarter of 2017, many companies have already reported their earnings results from the previous three months. Using earnings as a chance to review one's holdings helps justify the original investment thesis. I look...
Share
Health Finance, Merck & Co., Inc.
Understanding Aducanumab's Potential In Alzheimer's
Seeking AlphaSlingshot Insights
Summary Additional data from a Phase 1 trial on Aducanumab has been reported this summer, while the drug is in Phase 3 testing. This call will discuss the importance of that data and how the patient populations line up between the Phase...
Share
GlaxoSmithKline plc, Health Care Industry
Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise
ReutersReuters Staff
LONDON () - Drug company Concordia overcharged Britain’s health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country’s Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million...
Share
GlaxoSmithKline plc, Pfizer, Inc.
Drug firm Concordia overcharged NHS with 6,000% price rise
The GuardianJulia Kollewe
Canadian drug company Concordia has overcharged the NHS millions of pounds for a lifechanging thyroid drug, according to Britain’s competition watchdog. The Competition and Markets Authority said it had provisionally found that Concordia had “abused its dominant position to overcharge the NHS”...
Share
Health Finance, Pfizer, Inc.
Pfizer Inc. 2017 Q3 - Results - Earnings Call Slides
Seeking Alpha
The following slide deck was published by Pfizer Inc. in conjunction with their 2017 Q3 earnings call.
Share